(Wired) For a while there, Seres Therapeutics was the most promising name in poop. Located in Cambridge, Massachusetts—in the same building as Crispr Therapeutics, one of the key players in gene editing today—the biotech company has been trying to transform medicine by harnessing the billions of bacteria in people's intestines.
Those bacteria, plus others that live in and on the body, make up the human microbiome, an invisible world that is only recently coming into focus. Scientists now know that the wrong balance of bugs in your gut—a delicate ecosystem that can collapse as you age, travel, or even take new medication—can lead to all sorts of distress. Seres is one of the first startups aiming to design treatments that would manipulate the microbiome to repair bad guts and cure diseases.